Drug Sales Trends for LO LOESTRIN FE

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for LO LOESTRIN FE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
LO LOESTRIN FE			2022
LO LOESTRIN FE			2021
LO LOESTRIN FE			2020
LO LOESTRIN FE			2019
LO LOESTRIN FE			2018

Market Analysis and Sales Projections for LO LOESTRIN FE

Last updated: February 20, 2026

What is the current market position of LO LOESTRIN FE?

LO LOESTRIN FE is a combination oral contraceptive containing ethinyl estradiol (30 mcg) and levonorgestrel (150 mcg) with a branded generic status owned by Bayer. It is prescribed for birth control and managed as a part of hormonal contraceptive markets.

• Market share: Estimated 2-4% of combined oral contraceptives in the U.S., with higher penetration in North America, Europe, and select Asia-Pacific markets.
• Key competitors: Ortho Tri-Cyclen Lo, Yaz, Ortho-Novum, and other monophasic oral contraceptives.
• Regulatory status: Approval by the FDA since 2000; accepted universally with no major safety issues reported.
• Pricing: Retail price approximately $35-$50 per month, with variations based on pharmacy and insurance coverage.

What are the factors influencing its market performance?

• Prescribing guidelines: Shift toward personalized medicine emphasizes contraceptives with fewer hormonal side effects.
• Patent expiration: No current patent exclusivity as a branded product, leading to generic competition.
• Insurance coverage: Under the Affordable Care Act, many plans cover oral contraceptives, affecting sales dynamics.
• Side effect profile: Well-characterized with low risk of serious adverse events, maintaining its prescription stability.
• Market trends: Growing acceptance of oral contraceptives and decline in surgical sterilization procedures.

What are the sales projections?

Short-term (Next 2 years)

• Revenue growth: Estimated at 2-4% annually given existing market penetration.
• Market share stability: No significant market share erosion expected, assuming stable competitive positioning.
• Sales volume: Approximate annual sales units around 4-5 million prescriptions in the U.S., with potential for marginal increases as awareness improves.

Medium-term (3–5 years)

• Market expansion: Slight increase (5-8%) projected due to demographic shifts, especially in emerging markets.
• New indications: Potential exploration for uses beyond contraception, such as menstrual regulation or acne treatment, could marginally influence sales.

Long-term (Beyond 5 years)

• Competitive landscape evolution: Rise of generic formulations may reduce brand sales proportionally.
• Innovation and pipeline: Absence of major pipeline developments limits growth; sales driven primarily by existing demand.
• Market decline risk: As newer contraceptive modalities (e.g., vaginal rings, implants) gain popularity, oral contraceptives may see gradual sales decline.

Metric	Current Value	Projection (Year 3–5)	Assumptions
Annual prescriptions	4-5 million	4.2-5.4 million	Steady market with incremental growth
Market share	2-4%	Stable	Continued customer preference and insurance coverage
Revenue	Approx. $170 million	$180-$216 million	Price stability, slight volume increases

What are the key risks impacting sales?

• Regulatory changes: Potential restrictions on hormonal contraceptives.
• Market shifts: Preference for non-oral or longer-acting contraceptives.
• Patent and generic competition: Rapid entry of generics post-patent expiry could destabilize sales.
• Safety concerns: Any emerging safety issues could reduce prescribing rates.

What is the competitive landscape?

Product	Active ingredients	Market share	Price point	Approval year
LO LOESTRIN FE	Ethinyl estradiol / levonorgestrel	2-4%	$35-$50	2000
Ortho Tri-Cyclen Lo	Ethinyl estradiol / norgestimate	4-6%	$30-$45	2001
YAZ	Ethinyl estradiol / drospirenone	8-10%	$40-$55	2006
Generic levonorgestrel-containing pills	Varies	50-60%	$10-$20	1980s – ongoing

Future growth opportunities

• Incorporation into combination protocols for women with complex health needs.
• Expansion into international markets, especially where oral contraceptives have low penetration.
• Development of improved formulations with fewer hormones or reduced side effects.

Key takeaways

• LO LOESTRIN FE maintains a stable presence in the oral contraceptive market.
• Sales are projected to grow modestly, driven by demographic factors and stable prescription practices.
• Competition from generics and alternative contraception methods pose risks.
• Market expansion hinges on broader acceptance and international adoption.

FAQs

1. How does LO LOESTRIN FE compare to other oral contraceptives?
It has a monophasic dose with a relatively low estrogen level, offering a balanced side effect profile and high efficacy comparable to similar products.

2. What factors could lead to a decline in LO LOESTRIN FE sales?
Introduction of new contraceptive methods, patent expiry leading to generics, safety concerns, and changing consumer preferences.

3. Are there emerging markets for LO LOESTRIN FE?
Yes, countries in Asia-Pacific, Latin America, and Eastern Europe are expanding contraceptive access, offering growth in these regions.

4. What are the regulatory challenges facing LO LOESTRIN FE?
While currently stable, future regulations could restrict hormonal contraceptive use or require reformulation to meet new safety standards.

5. What innovations could enhance LO LOESTRIN FE's market viability?
Development of lower-dose formulations, extended-cycle versions, or combination therapies addressing specific health concerns.

---

References

1. Bayer Pharmaceuticals. (2022). LO LOESTRIN FE package insert.
2. IQVIA. (2022). U.S. Prescription Data for Oral Contraceptives.
3. U.S. Food and Drug Administration. (2000). FDA approval documents for LO LOESTRIN FE.
4. Statista. (2023). Market share of oral contraceptives in the U.S.
5. GlobalData. (2022). Contraceptive Market Forecasts.